HomeProductsBioactive CompoundsTGF-beta/Smad PathwayPKCMidostaurin
Chemical structure of CAS 120685-11-2

Midostaurin

In Stock•Starting at $55 for 50 mg•Purity ≥ 99%
CAS No.120685-11-2
MDL No.MFCD00871372
MFC35H30N4O4
MW570.60
InChI KeyBMGQWWVMWDBQGC-IIFHNQTCSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
50 mg99%$55In Stock
100 mg99%$90In Stock
250 mg99%$151In Stock
1 g99%$402In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Midostaurin is an N-benzoyl derivative of staurosporine, classified as an indolocarbazole and an organic heterooctacyclic compound. It functions as a protein kinase C (EC 2.7.11.13) inhibitor and an antineoplastic agent, and is also a member of the benzamide and gamma-lactam classes. It is functionally related to staurosporine.

CAS No.120685-11-2
Product NameMidostaurin
IrritantIrritant
Health HazardHealth Hazard
Environmental HazardEnvironmental Hazard
Signal Word:Danger
HCode:H302-H319-H335-H360-H361-H373-H400-H410
PCode:P203-P260-P261-P264-P264+P265-P270-P271-P273-P280-P301+P317-P304+P340-P305+P351+P338-P318-P319-P330-P337+P317-P391-P403+P233-P405-P501

Related Articles

Studies related to this compound and its mechanism of action

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Blood • Vol. 114, Issue 14 • 2009
PMID: 19654408PMC: PMC2756206DOI: 10.1182/blood-2009-05-222034

Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells.

Toxicology in vitro : an international journal published in association with BIBRA • Vol. 23, Issue 6 • 2009
PMID: 19573588DOI: 10.1016/j.tiv.2009.06.027

A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.

Clinical pharmacokinetics • Vol. 47, Issue 12 • 2008
PMID: 19026036DOI: 10.2165/0003088-200847120-00005

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells.

Blood • Vol. 110, Issue 2 • 2007
PMID: 17420286DOI: 10.1182/blood-2006-10-054411

Documentation

Similar Products